AbbVie 2013 Annual Report Download - page 101

Download and view the complete annual report

Please find page 101 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Note 14 Segment and Geographic Area Information
AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie’s U.S.
sales are to three wholesalers. Outside the United States, products are sold primarily to health care
providers or through distributors, depending on the market served. Worldwide net sales of key products
were as follows.
years ended December 31 (in millions) 2013 2012 2011
HUMIRA $10,659 $ 9,265 $ 7,932
AndroGel 1,035 1,152 874
Kaletra 962 1,013 1,170
Synagis 827 825 775
Lupron 785 800 810
Synthroid 622 551 522
Sevoflurane 568 602 665
Creon 412 353 332
Duodopa 178 149 125
Dyslipidemia products 1,076 2,145 2,504
All other 1,666 1,525 1,735
Net sales $18,790 $18,380 $17,444
Net sales to external customers, based on the country that sold the product, were as follows.
years ended December 31 (in millions) 2013 2012 2011
United States $10,181 $10,435 $ 9,712
Germany 911 756 701
The Netherlands 858 776 904
Japan 625 718 616
United Kingdom 606 552 496
Spain 543 525 569
France 540 500 516
Canada 538 500 446
Brazil 439 434 382
Italy 404 408 428
All other countries 3,145 2,776 2,674
Net sales $18,790 $18,380 $17,444
Long-lived assets include net property and equipment of $2.3 billion and $2.2 billion as of
December 31, 2013 and 2012, of which $1.6 billion and $1.6 billion, respectively, was located in the
United States and Puerto Rico and $591 million and $536 million, respectively, was located in Europe.
97